TY - JOUR AB - Serum autoantibodies respond not only to tumor‑associated antigens of hepatocellular carcinoma (HCC) but also to those of liver cirrhosis (LC) and chronic hepatitis (CH). The present prospective multi‑institutional study evaluated the diagnostic properties of six autoantibodies in distinguishing HCC from LC and CH. A total of 416 participants were enrolled: 149 With HCC, 76 with LC, 103 with CH and 88 healthy controls. Titers of serum autoantibodies to Sui1, RalA, p62, p53, c‑myc and NY‑ESO‑1 were determined using enzyme‑linked immunosorbent assays. All six antibodies were positive for HCC: s‑Sui1‑Abs (44%), s‑RalA‑Abs (23%), s‑p62‑Abs (21%), s‑p53‑Abs (13%), s‑c‑myc‑Abs (11%) and s‑NY‑ESO‑1‑Abs (6%). The positivity rates of all six antibodies combined were 5% for healthy controls, 52% for CH, 58% for LC and 66% for HCC. The positivity rates of s‑Sui1‑Abs, s‑RalA‑Abs and s‑p53‑Abs were higher for HCC compared with those of LC and CH. However, the positivity rates of s‑p62‑Abs, s‑c‑myc‑Abs and s‑NY‑ESO‑1‑Abs for HCC were not higher compared with those for LC and CH. Overall, autoantibodies were useful in differentiating patients with HCC from healthy individuals. However, they were not specific to HCC and were also present in the sera of individuals with CH and LC. These autoantibodies may be induced during the development of HCC. Clinical trial registration number: UMIN000014530 (date of registration 2011/07/11). AD - Department of Surgery, School of Medicine, Toho University, Tokyo 143‑8541, Japan Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba‑shi, Chiba 260‑8677, Japan Department of Surgery, Chiba Cancer Center, Chiba‑shi, Chiba 260‑8717, Japan Department of Gastroenterology, Japan Community Health Care Organization Chiba Hospital, Chiba‑shi, Chiba 260‑8710, Japan Department of Gastroenterology, Funabashi Municipal Medical Center, Funabashi, Chiba 273‑8588, Japan Department of Gastroenterology, Kimitsu Chuo Hospital, Kimitsu, Chiba 292‑8535, Japan Department of Gastroenterology, Japan Community Health Care Organization Funabashi Central Hospital, Funabashi, Chiba 273‑8556, Japan AU - Okada,Rei AU - Otsuka,Yuichiro AU - Yokosuka,Osamu AU - Kato,Naoya AU - Imazaki,Fumio AU - Hoshino,Isamu AU - Sugiura,Nobuyuki AU - Mizumoto,Hideaki AU - Azemoto,Ryousaku AU - Kato,Kazuki AU - Shimada,Hideaki DA - 2022/10/01 DO - 10.3892/ol.2022.13487 IS - 4 JO - Oncol Lett KW - hepatocellular carcinoma liver cirrhosis chronic hepatitis SEREX autoantibody tumor marker PY - 2022 SN - 1792-1074 1792-1082 SP - 367 ST - Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi‑institutional study T2 - Oncology Letters TI - Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi‑institutional study UR - https://doi.org/10.3892/ol.2022.13487 VL - 24 ER -